FY2025 EPS Estimates for Opthea Decreased by Leerink Partnrs

Opthea Limited (NASDAQ:OPT) – Investment analysts at Leerink Partnrs reduced their FY2025 earnings estimates for shares of Opthea in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.62) per share for the year, down from their previous estimate of ($1.15). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.37) EPS.

A number of other brokerages also recently issued reports on OPT. Oppenheimer downgraded Opthea from an “outperform” rating to a “market perform” rating in a research report on Monday. Leerink Partners cut shares of Opthea from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $12.00 to $1.00 in a research report on Tuesday. HC Wainwright downgraded shares of Opthea from a “buy” rating to a “neutral” rating and reduced their price target for the company from $12.00 to $2.00 in a research note on Tuesday. Jefferies Financial Group reaffirmed an “underperform” rating and set a $1.00 price objective (down previously from $8.00) on shares of Opthea in a research report on Tuesday. Finally, Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $1.33.

Opthea Trading Up 7.2 %

OPT opened at $3.41 on Thursday. The business’s 50 day moving average price is $4.42 and its 200 day moving average price is $4.07. Opthea has a one year low of $1.79 and a one year high of $6.30.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OPT. ABC Arbitrage SA purchased a new position in Opthea in the 4th quarter valued at approximately $40,000. OLD Mission Capital LLC purchased a new position in Opthea in the fourth quarter valued at $42,000. Twin Lakes Capital Management LLC purchased a new position in shares of Opthea in the 3rd quarter valued at about $81,000. Citadel Advisors LLC acquired a new position in shares of Opthea during the fourth quarter worth about $79,000. Finally, Jane Street Group LLC purchased a new stake in shares of Opthea during the third quarter worth approximately $114,000. Institutional investors and hedge funds own 55.95% of the company’s stock.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.